Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $34 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.